ArticleObesity pillars2026
Epidemiology of osteoarthritis overall and by body mass index category in the United States: A retrospective analysis of the National Health and Nutrition Examination Survey.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a known risk factor for both the incidence and progression of osteoarthritis (OA). This retrospective analysis describes the prevalence of OA and demographic, clinical, and prescription characteristics by body mass index (BMI) category. Methods: This was a retrospective, cross-sectional, observational, descriptive epidemiologic study based on the secondary analysis of the 2015-2016 and 2017-2018 National Health and Nutrition Examination Survey (NHANES) databases. Adults ≥ 20 years with self-reported OA were evaluated. Measures were reported overall and by BMI category (i.e., underweight, normal weight, overweight, class I, II, and III obesity) and included OA prevalence, demographics, comorbidities, weight-related self-reports, time since arthritis onset, and prescription arthritis medications used in the prior 30 days. Analyses were descriptive and weighted to be representative of the United States (US) population. Results: In total, 31,936,699 adults (aged ≥ 20 years) in the US had OA, with a prevalence (per 1000 persons) of 135.0 (95% confidence interval, 122.9-147.0). Prevalence was highest in adults aged ≥ 65 years (315.7) and increased by BMI category from 72.4 in underweight individuals to 191.4 in class III obesity. Approximately 30.2% of people with OA had overweight, and 51.8% had obesity (i.e., 25.1%, 14.9%, and 11.8% in obesity classes I, II, and III, respectively). At the survey date, people had been living with OA for a mean (standard error) of 13.5 (0.7) years. Common self-reported comorbidities included hypertension (58.4%), cancer/malignancies (25.4%), and thyroid problems (24.5%). Among people with OA, 57.8% reported that a doctor told them they had overweight, and 39.2% reported they were currently controlling or losing weight. The most commonly prescribed OA-related medications were nonsteroidal anti-inflammatory drugs and opioids (used in 16.2% and 13.9% of the population, respectively. Conclusion: The prevalence of OA in people with obesity class III was more than twice the prevalence in people with normal weight.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.